ROIV – Roivant Sciences Ltd

ROIV — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

4.79

Margin Of Safety %

Put/Call OI Ratio

0.75

EPS Next Q Diff

0.07

EPS Last/This Y

-0.73

EPS This/Next Y

-0.06

Price

26.39

Target Price

34.27

Analyst Recom

1.25

Performance Q

18.8

Upside

-157.6%

Beta

1.22

Ticker: ROIV

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ROIV	29.52	0.58	0.05	41406
2026-03-10	ROIV	29.73	0.58	0.28	41512
2026-03-11	ROIV	29.58	0.58	1.07	41545
2026-03-12	ROIV	28.56	0.59	0.45	42197
2026-03-13	ROIV	28.55	0.59	0.45	42197
2026-03-17	ROIV	28.31	0.59	0.61	42238
2026-03-18	ROIV	27.81	0.59	0.66	42257
2026-03-19	ROIV	27.81	0.59	0.20	42259
2026-03-20	ROIV	27.7	0.59	0.15	42264
2026-03-23	ROIV	27.93	0.74	0.56	31125
2026-03-24	ROIV	26.88	0.74	14.88	32145
2026-03-25	ROIV	27.37	0.74	9.04	32149
2026-03-26	ROIV	27.34	0.75	1.40	32265
2026-03-27	ROIV	26.51	0.75	0.73	32349
2026-03-30	ROIV	26.41	0.75	0.51	32613
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ROIV	29.52	-44.2	-	-0.97
2026-03-10	ROIV	29.73	-44.2	-	-0.97
2026-03-11	ROIV	29.58	-44.2	-	-0.97
2026-03-12	ROIV	28.55	-44.2	-	-0.97
2026-03-13	ROIV	28.08	-44.2	-	-0.97
2026-03-17	ROIV	28.30	-44.2	-	-0.97
2026-03-18	ROIV	27.81	-44.2	-	-0.97
2026-03-19	ROIV	27.80	-44.2	-	-0.97
2026-03-20	ROIV	27.70	-44.2	-	-0.97
2026-03-23	ROIV	27.90	-44.2	-	-0.97
2026-03-24	ROIV	26.88	-44.2	-	-0.97
2026-03-25	ROIV	27.36	-44.2	-	-0.97
2026-03-26	ROIV	27.33	-44.2	-	-0.97
2026-03-27	ROIV	26.51	-44.2	-	-0.97
2026-03-30	ROIV	26.39	-44.2	-	-0.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ROIV	-11.28	1.53	4.56
2026-03-10	ROIV	-11.28	1.53	4.56
2026-03-11	ROIV	-11.28	1.53	4.80
2026-03-12	ROIV	-11.28	1.53	4.80
2026-03-13	ROIV	-11.28	1.53	4.80
2026-03-17	ROIV	-11.28	2.11	4.80
2026-03-18	ROIV	-11.28	2.11	4.80
2026-03-19	ROIV	-11.29	2.11	4.80
2026-03-20	ROIV	-11.36	2.11	4.80
2026-03-23	ROIV	-11.36	2.12	4.80
2026-03-24	ROIV	-10.77	2.12	4.80
2026-03-25	ROIV	-10.77	2.12	4.79
2026-03-26	ROIV	-10.77	2.12	4.79
2026-03-27	ROIV	-10.77	2.12	4.79
2026-03-30	ROIV	-10.77	2.15	4.79
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

-0.36

Avg. EPS Est. Current Quarter

-0.31

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-10.77

Institutional Transactions

2.15

Beta

1.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

34.27

P/E

Forward P/E

PEG

P/S

1420.11

P/B

4.39

P/Free Cash Flow

EPS

-1.17

Average EPS Est. Cur. Y

-0.97

EPS Next Y. (Est.)

-1.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6079.94

Relative Volume

0.67

Return on Equity vs Sector %

-46.4

Return on Equity vs Industry %

-30.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.12

EBIT Estimation

◆ ROIV Healthcare

$26.41

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

25/25

Volume

9/15

Valuation

7/20

TP/AR

2/10

Options

3/10

RSI

41.4

Range 1M

Sup Dist

0.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

4/30

Estimates

1/20

Inst/Vol

7/15

Options

7/10

EPS Yr

-366.1%

EPS NY

-5.9%

52W%

81.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +29.8% upside

Quality

7/30

Valuation

6/30

Growth

0/25

Stability

7/10

LT Trend

0/5

Upside

+29.8%

Quality

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 750

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

RNAM – Avidity Biosciences Inc

RNAM — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

6.18

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

72.82

Target Price

Analyst Recom

Performance Q

2.13

Upside

N/A

Beta

0.98

Ticker: RNAM

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	RNAM	72.82	N/A	N/A	0
2026-03-10	RNAM	72.82	N/A	N/A	0
2026-03-11	RNAM	72.82	N/A	N/A	0
2026-03-12	RNAM	72.82	N/A	N/A	0
2026-03-13	RNAM	72.82	N/A	N/A	0
2026-03-17	RNAM	72.82	N/A	N/A	0
2026-03-18	RNAM	72.82	N/A	N/A	0
2026-03-19	RNAM	72.82	N/A	N/A	0
2026-03-20	RNAM	72.82	N/A	N/A	0
2026-03-23	RNAM	72.82	N/A	N/A	0
2026-03-24	RNAM	72.82	N/A	N/A	0
2026-03-25	RNAM	72.82	N/A	N/A	0
2026-03-26	RNAM	72.82	N/A	N/A	0
2026-03-27	RNAM	72.82	N/A	N/A	0
2026-03-30	RNAM	72.82	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

5 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	RNAM	0.00	0	0
2026-03-10	RNAM	0.00	0	0
2026-03-11	RNAM	0.00	0	6.18
2026-03-12	RNAM	0.00	0	6.18
2026-03-13	RNAM	0.00	0	6.18
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

5 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

602.56

P/B

6.52

P/Free Cash Flow

EPS

-4.96

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3650.39

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for RNAM

Avidity Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 511

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in clinical development, such as Delpacibart zotadirsen which is in Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy; Delpacibart etedesiran which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; and Delpacibart braxlosiran that is in Phase 1/2 development stage for the treatment of facioscapulohumeral muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. As of February 27, 2026, Avidity Biosciences, Inc. operates as a subsidiary of Novartis AG.

RNAM

Latest News

—

Caricamento notizie per RNAM…

stock quote shares RNAM – Avidity Biosciences Inc Stock Price stock today

news today RNAM – Avidity Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RNAM – Avidity Biosciences Inc yahoo finance google finance

stock history RNAM – Avidity Biosciences Inc invest stock market

stock prices RNAM premarket after hours

ticker RNAM fair value insiders trading

RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.07

Margin Of Safety %

Put/Call OI Ratio

1.52

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

23.39

Target Price

Analyst Recom

Performance Q

10.26

Upside

-100.6%

Beta

2.27

Ticker: RGC

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	RGC	25.44	2.34	0.66	5013
2026-03-10	RGC	24.65	2.22	0.50	4956
2026-03-11	RGC	23.7	2.03	0.04	5270
2026-03-12	RGC	23.9	1.93	1.58	5357
2026-03-13	RGC	24	1.93	1.60	5357
2026-03-17	RGC	22.88	1.81	0.82	5457
2026-03-18	RGC	26.47	1.81	0.42	5434
2026-03-19	RGC	26.97	1.74	0.09	5759
2026-03-20	RGC	27.2	1.71	0.60	5804
2026-03-23	RGC	25.02	1.41	1.87	2655
2026-03-24	RGC	24.3	1.52	1.88	2790
2026-03-25	RGC	24.3041	1.53	0.36	2867
2026-03-26	RGC	25.27	1.52	1.50	2872
2026-03-27	RGC	25.68	1.51	1.18	2880
2026-03-30	RGC	23.39	1.52	0.16	2871
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	RGC	25.71	-	-	-
2026-03-10	RGC	24.66	-	-	-
2026-03-11	RGC	23.80	-	-	-
2026-03-12	RGC	24.12	-	-	-
2026-03-13	RGC	23.15	-	-	-
2026-03-17	RGC	22.98	-	-	-
2026-03-18	RGC	26.39	-	-	-
2026-03-19	RGC	26.96	-	-	-
2026-03-20	RGC	27.20	-	-	-
2026-03-23	RGC	25.16	-	-	-
2026-03-24	RGC	24.30	-	-	-
2026-03-25	RGC	24.38	-	-	-
2026-03-26	RGC	25.32	-	-	-
2026-03-27	RGC	26.33	-	-	-
2026-03-30	RGC	23.39	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	RGC	0.00	-8.67	1.19
2026-03-10	RGC	0.00	-8.67	1.19
2026-03-11	RGC	0.00	-8.67	1.12
2026-03-12	RGC	0.00	-8.67	1.12
2026-03-13	RGC	0.00	-8.67	1.12
2026-03-17	RGC	0.00	-8.44	1.12
2026-03-18	RGC	0.00	-8.44	1.12
2026-03-19	RGC	0.00	-8.44	1.12
2026-03-20	RGC	0.00	-8.44	1.12
2026-03-23	RGC	0.00	-7.57	1.12
2026-03-24	RGC	0.00	-7.57	1.12
2026-03-25	RGC	0.00	-7.57	1.07
2026-03-26	RGC	0.00	-7.57	1.07
2026-03-27	RGC	0.00	-7.57	1.07
2026-03-30	RGC	0.00	-7.57	1.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-7.57

Beta

2.27

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.5

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

2373.35

P/Free Cash Flow

EPS

-0.01

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.18

Return on Equity vs Sector %

-101.2

Return on Equity vs Industry %

-80.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare

$23.33

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

15/25

Volume

11/15

Valuation

6/20

TP/AR

2/10

Options

3/10

RSI

43.5

Range 1M

33.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

11/30

Estimates

0/20

Inst/Vol

3/15

Options

6/10

EPS Yr

EPS NY

52W%

27.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

2/30

Growth

6/25

Stability

6/10

LT Trend

2/5

Quality

Regencell Bioscience Holdings L

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 10

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

RGC

Latest News

—

Caricamento notizie per RGC…

stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today

news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance

stock history RGC – Regencell Bioscience Holdings Ltd invest stock market

stock prices RGC premarket after hours

ticker RGC fair value insiders trading

ONC – BeOne Medicines Ltd ADR

ONC — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

1.49

Margin Of Safety %

Put/Call OI Ratio

1.43

EPS Next Q Diff

0.75

EPS Last/This Y

-2.59

EPS This/Next Y

3.83

Price

284.82

Target Price

410.21

Analyst Recom

1.26

Performance Q

-9.06

Upside

-69.0%

Beta

0.57

Ticker: ONC

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	ONC	302.22	1.86	0.00	3042
2026-03-10	ONC	305.32	1.87	9.00	3037
2026-03-11	ONC	299.08	1.88	0.68	3047
2026-03-12	ONC	285.45	1.70	3.50	3176
2026-03-13	ONC	285.3	1.70	3.50	3176
2026-03-17	ONC	287.13	1.70	999.99	3186
2026-03-18	ONC	282.41	1.69	2.25	3176
2026-03-19	ONC	282.93	1.69	0.40	3170
2026-03-20	ONC	275.29	1.40	0.73	3406
2026-03-23	ONC	274.47	1.52	0.12	3182
2026-03-24	ONC	275.66	1.48	2.00	3209
2026-03-25	ONC	283.51	1.47	0.13	3203
2026-03-26	ONC	277.13	1.45	0.25	3235
2026-03-27	ONC	282.5	1.43	1.22	3252
2026-03-30	ONC	284.18	1.43	0.75	3264
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	ONC	302.50	7640.0	618.0	5.50
2026-03-10	ONC	304.75	7640.0	344.4	5.50
2026-03-11	ONC	300.28	7640.0	307.0	5.50
2026-03-12	ONC	287.06	7640.0	290.6	5.50
2026-03-13	ONC	283.51	7640.0	292.8	5.50
2026-03-17	ONC	287.25	7640.0	312.1	5.50
2026-03-18	ONC	282.50	7640.0	302.4	5.50
2026-03-19	ONC	282.86	8070.0	318.3	5.47
2026-03-20	ONC	276.08	8070.0	323.0	5.47
2026-03-23	ONC	275.46	8070.0	326.5	5.47
2026-03-24	ONC	275.83	8070.0	368.4	5.47
2026-03-25	ONC	282.94	8070.0	317.9	5.47
2026-03-26	ONC	276.48	8070.0	294.4	5.47
2026-03-27	ONC	282.20	8070.0	328.5	5.47
2026-03-30	ONC	284.82	8070.0	284.8	5.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	ONC	-24.80	0.60	1.40
2026-03-10	ONC	-24.52	0.60	1.40
2026-03-11	ONC	-24.52	0.60	1.35
2026-03-12	ONC	-24.01	0.60	1.35
2026-03-13	ONC	-22.99	0.60	1.35
2026-03-17	ONC	-22.99	0.72	1.35
2026-03-18	ONC	-22.99	0.72	1.35
2026-03-19	ONC	-19.89	0.72	1.35
2026-03-20	ONC	-19.89	0.72	1.35
2026-03-23	ONC	-19.89	0.62	1.47
2026-03-24	ONC	-21.25	0.62	1.47
2026-03-25	ONC	-21.25	0.62	1.49
2026-03-26	ONC	-21.25	0.62	1.49
2026-03-27	ONC	-21.25	0.62	1.49
2026-03-30	ONC	-21.25	0.59	1.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

0.58

Avg. EPS Est. Current Quarter

0.82

Avg. EPS Est. Next Quarter

1.33

Insider Transactions

-21.25

Institutional Transactions

0.59

Beta

0.57

Average Sales Estimate Current Quarter

1437

Average Sales Estimate Next Quarter

1566

Fair Value

296.14

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.2

Max Drawdown 5-Year %

-70

Target Price

410.21

P/E

112.6

Forward P/E

29.76

PEG

0.42

P/S

5.41

P/B

7.22

P/Free Cash Flow

30.7

EPS

2.52

Average EPS Est. Cur. Y

5.47

EPS Next Y. (Est.)

9.3

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

5.37

Relative Volume

0.56

Return on Equity vs Sector %

-20.9

Return on Equity vs Industry %

-4.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.79

EBIT Estimation

284.8

◆ ONC Healthcare

$284.08

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

20/25

Volume

11/15

Valuation

18/20

TP/AR

2/10

Options

2/10

RSI

39.5

Range 1M

27.8%

Sup Dist

1.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

25/30

Estimates

5/20

Inst/Vol

4/15

Options

4/10

EPS Yr

131.1%

EPS NY

57.1%

52W%

46.1%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +17.4% upside

Quality

10/30

Valuation

8/30

Growth

17/25

Stability

6/10

LT Trend

0/5

Upside

+17.4%

Quality

MoS

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

MDLN – Medline Inc

MDLN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.57

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.34

EPS Last/This Y

0.04

EPS This/Next Y

0.19

Price

42.63

Target Price

53.77

Analyst Recom

1.48

Performance Q

-3.42

Upside

-25.2%

Beta

Ticker: MDLN

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	MDLN	43.4	0.23	0.22	41873
2026-03-10	MDLN	42.85	0.23	0.58	41409
2026-03-11	MDLN	42.35	0.24	0.08	41787
2026-03-12	MDLN	41.06	0.24	0.88	41825
2026-03-13	MDLN	41.07	0.24	0.87	41825
2026-03-17	MDLN	42.17	0.25	0.88	42721
2026-03-18	MDLN	42.23	0.25	0.19	42715
2026-03-19	MDLN	43.57	0.25	0.20	42809
2026-03-20	MDLN	42.69	0.25	0.87	43175
2026-03-23	MDLN	42.42	0.31	0.00	15844
2026-03-24	MDLN	42.04	0.14	0.89	31045
2026-03-25	MDLN	42.46	0.15	0.17	31212
2026-03-26	MDLN	42.19	0.15	0.05	31320
2026-03-27	MDLN	41.4	0.15	2.14	31355
2026-03-30	MDLN	42.63	0.26	0.60	36757
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	MDLN	43.42	-	527.7	-
2026-03-10	MDLN	42.84	-	519.7	-
2026-03-11	MDLN	42.36	-	521.8	-
2026-03-12	MDLN	41.06	-	483.3	-
2026-03-13	MDLN	41.44	-	564.2	1.47
2026-03-17	MDLN	42.18	-	566.4	1.47
2026-03-18	MDLN	42.23	-	549.3	1.47
2026-03-19	MDLN	43.58	-	609.2	1.47
2026-03-20	MDLN	42.69	-	504.6	1.47
2026-03-23	MDLN	42.42	-	533.2	1.47
2026-03-24	MDLN	42.03	-	524.9	1.47
2026-03-25	MDLN	42.65	-	575.2	1.47
2026-03-26	MDLN	42.24	-	525.9	1.47
2026-03-27	MDLN	41.35	-	505.5	1.47
2026-03-30	MDLN	42.63	-	606.7	1.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	MDLN	-10.60	-5.30	1.62
2026-03-10	MDLN	-10.60	-5.30	1.62
2026-03-11	MDLN	-10.60	-5.30	1.82
2026-03-12	MDLN	-28.17	-5.30	1.82
2026-03-13	MDLN	-30.40	-5.30	1.82
2026-03-17	MDLN	-30.40	-5.30	1.82
2026-03-18	MDLN	-30.40	-5.30	1.82
2026-03-19	MDLN	-30.40	-5.30	1.82
2026-03-20	MDLN	-30.40	-5.30	1.82
2026-03-23	MDLN	-30.40	4.61	1.82
2026-03-24	MDLN	-30.40	4.61	1.82
2026-03-25	MDLN	-30.40	4.61	2.57
2026-03-26	MDLN	-30.40	4.61	2.57
2026-03-27	MDLN	-30.40	4.61	2.57
2026-03-30	MDLN	-30.40	24.96	2.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

-0.01

Avg. EPS Est. Current Quarter

0.29

Avg. EPS Est. Next Quarter

0.33

Insider Transactions

-30.4

Institutional Transactions

24.96

Beta

Average Sales Estimate Current Quarter

7162

Average Sales Estimate Next Quarter

7488

Fair Value

48.2

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.2

Max Drawdown 5-Year %

Target Price

53.77

P/E

29.48

Forward P/E

25.77

PEG

2.67

P/S

1.97

P/B

3.22

P/Free Cash Flow

44.3

EPS

1.45

Average EPS Est. Cur. Y

1.47

EPS Next Y. (Est.)

1.66

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

4.08

Relative Volume

1.55

Return on Equity vs Sector %

-16.6

Return on Equity vs Industry %

1.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

606.7

◆ MDLN Healthcare

$42.62

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

17/25

Volume

3/15

Valuation

14/20

TP/AR

2/10

Options

6/10

RSI

46.5

Range 1M

23.7%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

11/30

Estimates

2/20

Inst/Vol

8/15

Options

9/10

EPS Yr

2.8%

EPS NY

12.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +2% upside

Quality

3/30

Valuation

4/30

Growth

7/25

Stability

4/10

LT Trend

0/5

Upside

+2%

Quality

MoS

13%

Medline Inc.

Sector: Healthcare

Industry: Medical Instruments & Supplies

Employees: 45000

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.

MDLN

Latest News

—

Caricamento notizie per MDLN…

stock quote shares MDLN – Medline Inc Stock Price stock today

news today MDLN – Medline Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MDLN – Medline Inc yahoo finance google finance

stock history MDLN – Medline Inc invest stock market

stock prices MDLN premarket after hours

ticker MDLN fair value insiders trading

COGT – Cogent Biosciences Inc

COGT — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

11.53

Margin Of Safety %

Put/Call OI Ratio

0.75

EPS Next Q Diff

-0.69

EPS Last/This Y

0.01

EPS This/Next Y

1.46

Price

35.4

Target Price

54.17

Analyst Recom

1.31

Performance Q

-8.98

Upside

-353.2%

Beta

0.52

Ticker: COGT

15 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	COGT	36.85	0.60	0.13	17509
2026-03-10	COGT	36.72	0.60	0.23	17511
2026-03-11	COGT	36.08	0.60	0.01	17519
2026-03-12	COGT	35.36	0.59	0.55	17746
2026-03-13	COGT	35.33	0.59	0.54	17746
2026-03-17	COGT	35.4	0.58	0.54	18162
2026-03-18	COGT	34.53	0.58	0.38	18186
2026-03-19	COGT	34.6	0.58	0.63	18162
2026-03-20	COGT	33.4	0.58	0.11	18165
2026-03-23	COGT	35.57	0.62	3.17	15664
2026-03-24	COGT	34.8	0.86	0.00	19492
2026-03-25	COGT	36.48	0.80	0.14	20312
2026-03-26	COGT	36.88	0.79	0.09	20459
2026-03-27	COGT	36.12	0.79	0.00	20518
2026-03-30	COGT	35.41	0.75	0.23	21162
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

15 items 1 of 1

15 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-09	COGT	37.03	-5.7	-	-2.13
2026-03-10	COGT	36.73	-5.7	-	-2.13
2026-03-11	COGT	36.09	-5.7	-	-2.13
2026-03-12	COGT	35.33	-5.7	-	-2.13
2026-03-13	COGT	33.95	-5.7	-	-2.13
2026-03-17	COGT	35.40	-3.9	-	-2.13
2026-03-18	COGT	34.37	-3.9	-	-2.13
2026-03-19	COGT	34.61	-3.9	-	-2.13
2026-03-20	COGT	33.38	-3.9	-	-2.15
2026-03-23	COGT	35.42	-3.9	-	-2.15
2026-03-24	COGT	34.92	-3.9	-	-2.15
2026-03-25	COGT	36.47	-3.9	-	-2.15
2026-03-26	COGT	36.90	-3.9	-	-2.15
2026-03-27	COGT	36.11	-3.9	-	-2.15
2026-03-30	COGT	35.40	-3.9	-	-2.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

15 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-09	COGT	-12.38	8.29	12.03
2026-03-10	COGT	-12.38	8.29	12.03
2026-03-11	COGT	-12.38	8.29	11.90
2026-03-12	COGT	-12.38	8.29	11.90
2026-03-13	COGT	-12.38	8.29	11.90
2026-03-17	COGT	-12.38	0	11.90
2026-03-18	COGT	-12.38	0	11.90
2026-03-19	COGT	-12.38	0	11.90
2026-03-20	COGT	-12.38	0	11.90
2026-03-23	COGT	-12.38	0	11.90
2026-03-24	COGT	-12.38	0	11.90
2026-03-25	COGT	-12.38	0	11.53
2026-03-26	COGT	-12.38	0	11.53
2026-03-27	COGT	-12.38	0	11.53
2026-03-30	COGT	-12.38	0	11.53
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

0.15

Avg. EPS Est. Current Quarter

-0.54

Avg. EPS Est. Next Quarter

-0.54

Insider Transactions

-12.38

Institutional Transactions

Beta

0.52

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-76.3

Target Price

54.17

P/E

Forward P/E

PEG

P/S

P/B

10.42

P/Free Cash Flow

EPS

-2.56

Average EPS Est. Cur. Y

-2.15

EPS Next Y. (Est.)

-0.69

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.78

Return on Equity vs Sector %

-79.1

Return on Equity vs Industry %

-62.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.26

EBIT Estimation

◆ COGT Healthcare

$35.39

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

9/25

Volume

9/15

Valuation

7/20

TP/AR

2/10

Options

5/10

RSI

46.3

Range 1M

42%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

14/30

Estimates

0/20

Inst/Vol

1/15

Options

6/10

EPS Yr

0.7%

EPS NY

70%

52W%

79%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +53.1% upside

Quality

2/30

Valuation

10/30

Growth

10/25

Stability

6/10

LT Trend

1/5

Upside

+53.1%

Quality

Cogent Biosciences, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

COGT

Latest News

—

Caricamento notizie per COGT…

stock quote shares COGT – Cogent Biosciences Inc Stock Price stock today

news today COGT – Cogent Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch COGT – Cogent Biosciences Inc yahoo finance google finance

stock history COGT – Cogent Biosciences Inc invest stock market

stock prices COGT premarket after hours

ticker COGT fair value insiders trading

No more stocks to show

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

RNAM – Avidity Biosciences Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RNAM

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y